Blinatumomab is the first FDA-approved BiTE and has now been approved for three indications: consolidation phase of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL), MRD-positive CD19-positive BCP-ALL in first or second complete remission, and in relapsed or refractory CD19-positive BCP-ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.